Advaxis, Inc. Completes Enrollment in Phase 2 Cervical Cancer Study

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy. The trial is designed to assess if ADXS-HPV can be safely administered in combination with and without cisplatin chemotherapy. The primary endpoint of this trial is overall survival.

Back to news